Study explorer (study characteristics and results) method abbreviations

display ongoing studies
Study studied treatmentcontrol treatmentpatientsrisk of biassample sizes Results

COVID 19 hospitalized meta-analysis

ConPlas-19, 2020
 
NCT04345523
RCTconvalescent plasma treatmentstandard of careCOVID 19 hospitalizedsome concern
38/43 inconclusive
    no demonstrated benefit a
Gharbharan et al., 2020
 
NCT04342182
RCTconvalescent plasma treatmentstandard of careCOVID 19 hospitalizedsome concern
43/43 inconclusive
  • inconclusive 5 % decrease in deaths (PE) with a moderate degree of certainty due to some concern in risk of bias
Abolghasemi, 2020
 
IRCT20200325046860N1
OBSconvalescent plasma treatmentcontrolCOVID 19 hospitalizedcritical
115/74 inconclusive
    no demonstrated benefit a

COVID-19 mild to moderate meta-analysis

PLACID, 2020
 
CTRI/2020/04/024775
RCTconvalescent plasma treatmentstandard of careCOVID-19 mild to moderatehigh
235/229 suggested
  • inconclusive 7 % increase in death or transfer to ICU (PE) but with a low degree of certainty due to high risk of bias
  • suggested 20 % increase in PCR-negative conversion (7-day) but with a low degree of certainty due to high risk of bias

COVID-19 severe or critically meta-analysis

Li, 2015
 
ChiCTR2000029757
RCTconvalescent plasma treatmentstandard of careCOVID-19 severe or criticallysome concern
52/51 inconclusive
    no demonstrated benefit a
  • inconclusive 40 % increase in clinical improvement (PE) with a moderate degree of certainty due to some concern in risk of bias
Duan, 2020OBSconvalescent plasma treatmentcontrolCOVID-19 severe or criticallycritical
10/10 inconclusive
    no demonstrated benefit a
Hegerova, 2020OBSconvalescent plasma treatmentcontrolCOVID-19 severe or criticallycritical
20/20 inconclusive
    no demonstrated benefit a
Rasheed, 2020OBSconvalescent plasma treatmentcontrolCOVID-19 severe or criticallycritical
21/28 inconclusive
    no demonstrated benefit a
Sean, 2020OBSconvalescent plasma treatmentcontrolCOVID-19 severe or criticallycritical
39/156 inconclusive
    no demonstrated benefit a
Joyner, 2020
 
NCT04338360
NRaconvalescent plasma treatmentconvalescent plasma treatmentCOVID-19 severe or criticallyserious
515/561 inconclusive
    no demonstrated benefit a

PE: primary endpoint; (a): to be demonstrated a result must be statistically significant on a primary endpoint (with multiplicity adjustment if necessary);